Cryoablation and immunotherapy for advanced gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial uses a freezing technique (cryoablation) combined with an immunotherapy drug (PD-1 inhibitor) for people with advanced stomach cancer that has spread or cannot be removed by surgery. It's for those whose cancer has continued to grow after one or two types of chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your stomach cancer is stage IV (has spread or can't be removed by surgery) and has grown after 1-2 chemotherapy treatments
- You are between 18 and 80 years old
- You have a type of stomach cancer called adenocarcinoma or neuroendocrine tumor
- Your doctor expects you to live more than 3 months and your distant cancer spread is under control
- You have adequate liver, kidney, and blood function (blood tests will confirm this)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that freezes part of the stomach tumor (cryoablation) combined with an immunotherapy drug (PD-1 inhibitor) as continued therapy for advanced stomach cancer. It may help people whose cancer has spread and who cannot have surgery.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests whether adding an immunotherapy drug (adebrelimab) with or without another targeted drug (apatinib) to standard chemotherapy is more effective for advanced stomach cancer. It aims to shrink tumors and improve outcomes for people who haven't had prior treatment for advanced disease.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.